

Malignancy in Myanmar with focus on cervical cancer


Ed Wilkins



Aim for today

- What are the types of cancer seen in HIV?
- What characteristics do ADM share/not share?
- Which ADM and NADM are common in Myanmar?
- Distinguishing HIV related cancers from OI's
- What is the relationship between HIV and cervical cancer?
- What characteristics do cervical cancer share/not share?







ADM and NADM

- AIDS-defining malignancies (ADM)
- Kaposi's sarcoma
- Non-Hodgkin lymphoma
- Primary CNS lymphoma
- Cervical cancer




ADM and **NADM**




Non-AIDS defining malignancies (NADM)

- Anal cancer
- Hodgkin disease
- Hepatoma
- Lung cancer
- Testicular cancer
- SCC conjunctiva, mucous membranes
- Many other sites..





Both are more common in HIV than in non-HIV



Both are associated with increasing rates with lower CD4 counts

Mortality rates by CD4 count in individuals with ADM and non-ADM

Latest CD4	Person- years (py)	Non-ADM		ADM	
count (/ μL)		Rate (/1000py) (n)	Relative risk*	Rate (/1000py) (n)	Relative risk*
<50	2335	6.0 (14)	15 (<0.001)	20.1 (47)	175 (<0.001)
50–99	2295	9.6 (22)	19 (<0.001)	4.8 (11)	41 (<0.001)
100–199	8097	6.8 (55)	10 (<0.001)	2.8 (23)	24 (<0.001)
200–349	21,048	2.0 (43)	3 (<0.001)	0.7 (14)	6 (<0.001)
350–499	24,052	1.1 (27)	2 (0.03)	0.3 (7)	3 (0.09)
500+	46,903	0.6 (27)	1 (-)	0.1 (5)	1 (-)



^{*}Adjusted for cohort, age, gender, smoking status, weight, transmission group, ethnicity, prior non-fatal non-neoplastic AIDS, HCV and HBV status, cART exposure, and latest HIV-RNA level

Both are associated with oncogenic viruses

AIDS-Defining

Oncogenic virus

Kaposi's Sarcoma

HHV-8 EBV, HHV-8

Non-Hodgkin's Lymphoma

EBV

PCNSLInvasive Cervical Carcinoma

HPV

Non-AIDS Defining (e.g.)

Anogenital cancers
 HPV


Hodgkin's Disease
 EBV

Leiomyosarcoma (pediatric)
 EBV

Squamous Conjunctival Carcinoma HPV


oesophagus, larynx, lip

Hepatoma HBV, HCV






For ADM the absolute risk is greater and varies more by type and CD4 count





ADM incidence has fallen sharply with use of ART




NADM incidence has increased as ADM has decreased (USA 1991-2005)

HIV-AIDS cancer match study USA

AIDS-defining malignancy

□ 0-12 years ■13-19years ■ 20-29 years ■30-39 years ■40-49 years ■50-59 years 60 years and older ncidence Rate per

Non-AIDS-defining malignancy






Factors Contributing to the Increase in NADM cases in HIV


- 4-fold increase in HIV/AIDS Population
- Patients living longer and not dying of OI
- Rising proportion of HIV pts > 50 yo
- Cancer incidence increases with age
- Greater and earlier start to smoking in HIV
- Increase in some CA incidence rate among HIV
 - Lung (3X), anal (29X), liver (3X), HL (13X)
 - Suggests may be additional risk from HIV



ART reduced the incidence of ADM but not NADM




Crude Incidence Rates of Cancer Among 20,775 HIV-Positive Patients Enrolled in Kaiser Permanente California (1996-2008), by ART Use Status






Myanmar: age standard incidence cancer and mortality rates




Kaposi's sarcoma: Myanmar Age specific rate 0.03/10⁵




KS by region: incidence and mortality

International Agency for Research on CaKaposi sarcoma: both sexes, all ages




Non-Hodgkin's Lymphoma: Myanmar Age specific rate 3.54/10⁵



NHL by region: incidence and mortality


International Agency for Research Non-Hodgkin lymphoma: both sexes, all ages




Current and predicted increase of KS and NHL

International Agency for Research on Cancer
Myanmar


Non-Hodgkin lymphoma, Kaposi sarcoma Number of new cancers in 2020 (all ages)



Cervical cancer: Myanmar Age specific rate 20.57/10⁵




Cervical cancer: incidence and mortality




Mortality

Current and predicted increase of cervical cancer

International Agency for Research on Cancer




Number of new cancers in 2020 (all ages)




GLOBOCAN 2012 (IARC) (24.4.2016)









Myanmar: age standard incidence cancer and mortality rates




Lung cancer: Myanmar Age specific rate 20.2/10⁵



Liver cancer: Myanmar Age specific rate 6.41/10⁵








Patient


- 37y-old ex-IDU for 8y
- Travelled Asia/Europe ++
- PMH pulmonary TB 1998,
 HCV +ve (RNA –ve)
- Presented with 6w history of fever, sweats, loss of weight
- HIV +ve, CD4 280 cells/mm³,
 VL 295,000 c/ml
- On methadone





Time course of symptoms





Differential diagnosis – peripheral and mediastinal lymphadenopathy

HIV disease and malignancies

- Progressive generalised lymphadenopathy
- Non-Hodgkin's lymphoma
- Hodgkin's lymphoma
- Multicentric
 Castleman's disease

Opportunistic infections

- TB
- MAI
- Penicilliosis
- Histoplasmosis
- Cryptococcus

CD4 of 280...

HIV disease and malignancies


- Progressive generalised lymphadenopathy
- Non-Hodgkin's lymphoma (BL)
- Hodgkin's lymphoma
- Multicentric
 Castleman's disease

Opportunistic infections

- TB
- MAI
- Penicilliosis
- Histoplasmosis
- Cryptococcus

Biopsy result revealed Hodgkin's disease

- Biopsy Reed-Sternberg cell
- CT:
 - Mediastinal mass, splenomegaly



- Bone marrow clear
- CSF cytology clear
- Type B symptoms: fever, loss of weight or night sweats
- Stage 3b



Lymphoma is more than one condition and not all are classical ADM

		Median CD4 range at diagnosis	Infective factor/ co-factor
NHL:	Burkitt's	350–500	EBV
	Diffuse large B-cell	10–150	EBV
	PCNSL	10–50	EBV
Primary effusion lymphoma		100–200	HHV-8
Hodgkin's lymphoma		100-500	EBV
Castleman's disease		100-300	HHV-8



Few facts about Hodgkin's disease

- It is a non-AIDS defining malignancy (NADM)
- 10-20x commoner in HIV
- 90% have 'B' symptoms
- 74–92% have advanced stages of disease
- Frequent involvement of extra-nodal sites:
 - Bone marrow (40–50%); Liver (15–40%) and spleen (20%)
- HIV-HL tends to develop as an earlier manifestation of HIV
- Higher CD4 and often ART suppressed




Few facts about non-Hodgkin's lymphoma

- Second most common malignancy in HIV
- AIDS defining (ADM) but Burkitt's lymphoma occurs at higher CD4 count
- Several pathological types
- Prognosis improved with additional HAART and approaching that seen in HIV-negative persons
- Frequent extranodal sites involved
- HIV-related primary effusion lymphoma (PEL) is linked to HHV8 and is rare
 - Very poor prognosis



Presentation usually associated with lymphadenopathy

- Majority of patients present with:
 - Type B symptoms fevers, sweats and weight loss
 - Lymphadenopathy which may be generalised or localised







Half have visceral/extra-nodal disease

- Extra-nodal disease is common
- Sites of extra-nodal involvement include:
 - Oral cavity
 - Liver, spleen
 - GI tract (ileum)
 - Lung
 - Skin
 - Bone-marrow






















HPV/HIV link





Cervical Cancer

- Latest data on cervical cancer incidence and mortality (GLOBOCAN 2012, IARC*):
 - 4th most common cancer in women
 - Globally 528,000 cases diagnosed in 2012:
 - 86% of all cases (n=453,032) in developing world
 - Globally 274,967 deaths:
 - 88% of all deaths (n=241,818) in developing world
- Mortality to incidence ratio:
 - Developed countries: 36–43%
 - Developing countries: 54–80%


*www.iarc.fr/globocan2008




Association between HIV, CIN, and Cervical Cancer

- In HIV-positive women, there is a higher incidence of:
 - HPV infection (70-80% vs. 30%)
 - Persistent HPV with multiple and high-risk types (16/18)
 - Cervical cancer precursors (CIN)
 - Cervical cancer
- ART has minimal effect on CIN progression

Association between HPV and HIV




Source: Palefsky. Curr Opin Oncol 2003.






It is more common in HIV-infected persons






Significant association between CIN and HIV and with low CD4











Relative risk and relationship to CD4 is much less than with other ADM's





There has been little change in incidence and no impact from ART




HPV vaccines are available and highly effective



Potential to eradicate all HPV-related disease


Relative reduction of genital warts aged 16-28 with vaccination programme






Reduction in most oncogenic strains

Differences in HPV Genoprevalence Between Pre-vaccine and Postvaccine Female Populations in Australia





CIN III reduction in young women






Lastly, a screening programme exists which is highly effective

- Increased rate of Cervical Ca can be avoided with regular screening programmes
 - Rates before and after screening reduced 5-10 fold
 - 75% of cases of cancer can be prevented
 - Increased rate associated with HIV can be abolished with screening
- All HIV-infected women should have annual cytology
 - Same age range as for HIV-negative women (1B)







Aim for today

- What are the types of cancer seen in HIV?
- What characteristics do ADM share/not share?
- Which ADM and NADM are common in Myanmar?
- Distinguishing HIV related cancers from OI's
- What is the relationship between HIV and cervical cancer?
- What characteristics do cervical cancer share/not share?







Malignancy in Myanmar with focus on cervical cancer